News Releases

03 Feb '22
CAMBRIDGE, Mass. & MONTREAL --(BUSINESS WIRE)--Feb. 3, 2022-- Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics,
Displaying 1 - 10 of 12